Vir Biotechnology to Provide Corporate Update and Report Second Quarter 2021 Financial Results on August 5, 2021
Rhea-AI Summary
Vir Biotechnology (Nasdaq: VIR) announced it will provide a corporate update along with its financial results for Q2 2021 on August 5, 2021. The press release will be accessible after market close on their website. Vir focuses on combining immunologic insights with advanced technologies to combat serious infectious diseases, with a development pipeline that includes candidates targeting COVID-19, hepatitis B, influenza A, and HIV.
Positive
- Scheduled corporate update and Q2 2021 financial results on August 5, 2021.
- Development pipeline includes multiple candidates targeting significant infectious diseases.
Negative
- None.
News Market Reaction
On the day this news was published, VIR declined 1.23%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
SAN FRANCISCO, July 22, 2021 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the Company will provide a corporate update and report financial results for the second quarter ended June 30, 2021 on Thursday, August 5, 2021.
The update will be provided via a press release after market close and will be accessible under Press Releases in the Investors section of the Vir website at www.vir.bio.
About Vir Biotechnology
Vir Biotechnology is a clinical-stage immunology company focused on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. Vir has assembled four technology platforms that are designed to stimulate and enhance the immune system by exploiting critical observations of natural immune processes. Its current development pipeline consists of product candidates targeting COVID-19, hepatitis B virus, influenza A and human immunodeficiency virus. For more information, please visit www.vir.bio.
FAQ
When will Vir Biotechnology release its Q2 2021 financial results?
What diseases is Vir Biotechnology targeting in its development pipeline?
How can I access the corporate update from Vir Biotechnology?
